Biotechs aim to extend popular grant, tax credit program

Biotechs are going hat in hand to Washington, again, hoping to extend a popular tax credit and grant program by as much as $5 billion over five years.
Whether the call for help is heard by a Congress focused on trimming the federal budget at all costs is another matter, but industry leaders say biotech and medical device companies are as much in peril as they were when the original program kicked in last year.